Payment overview · 2025
General Payments
$111.41
1 reported records · 1 companies
Healthcare provider profile · identity verified
Michael Warren Kaplan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ORLANDO, FL · NPI 1184121154
Verified facts
What the public records show
CMS Open Payments records show Michael Warren Kaplan, MD received $111.41 in general payments during 2025 across 1 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 100.0% of that reported general-payment amount.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.41 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $111.41 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 509 | 197 |
| Metformin Hcl | Metformin Hcl | 245 | 92 |
| Lisinopril | Lisinopril | 235 | 96 |
| Losartan Potassium | Losartan Potassium | 233 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 56 |
| Gabapentin | Gabapentin | 165 | 78 |
| Furosemide | Furosemide | 151 | 64 |
| Carvedilol | Carvedilol | 143 | 59 |
| Warfarin Sodium | Warfarin Sodium | 141 | 24 |
| Alprazolam | Alprazolam | 135 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 58 |
| Omeprazole | Omeprazole | 131 | 57 |
| Glipizide | Glipizide | 123 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 46 |
| Simvastatin | Simvastatin | 100 | 39 |
| Alendronate Sodium | Alendronate Sodium | 97 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 38 |
| Trazodone Hcl | Trazodone Hcl | 80 | 31 |
| Eliquis | Apixaban | 79 | 22 |
| Atenolol | Atenolol | 73 | 22 |
| Allopurinol | Allopurinol | 67 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 30 |
| Bupropion Hcl Sr | Bupropion Hcl | 59 | 21 |
| Azithromycin | Azithromycin | 54 | 38 |
| Spironolactone | Spironolactone | 54 | 23 |
| Ozempic | Semaglutide | 53 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 24 |
| Bupropion Xl | Bupropion Hcl | 50 | 14 |
| Famotidine | Famotidine | 50 | 29 |
| Tramadol Hcl | Tramadol Hcl | 50 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 18 |
| Lorazepam | Lorazepam | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 16 |
| Metformin Hcl Er | Metformin Hcl | 41 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 33 |
| Prednisone | Prednisone | 40 | 14 |
| Nifedipine Er | Nifedipine | 39 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 20 |
| Ibuprofen | Ibuprofen | 36 | 28 |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Montelukast Sodium | Montelukast Sodium | 32 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 31 | 11 |
| Finasteride | Finasteride | 30 | 16 |
| Latanoprost | Latanoprost | 30 | 11 |
| Valsartan | Valsartan | 30 | 11 |
| Buspirone Hcl | Buspirone Hcl | 29 | 14 |
| Lactulose | Lactulose | 29 | 11 |
| Tadalafil | Tadalafil | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 26 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 26 | suppressed |
| Meloxicam | Meloxicam | 25 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 19 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | 11 |
| Baclofen | Baclofen | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | 11 |
| Jardiance | Empagliflozin | 21 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $111.41 · 1 records | Boehringer Ingelheim Pharmaceuticals, Inc. | — | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error